Clinical Trial Update: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). [Phase 2]

View source ↗

Summary

A Phase 2 study (NP05) evaluating LY3857210 in diabetic peripheral neuropathic pain has completed, with results posted in August 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathic Pain
• Diabetic Peripheral Neuropathy

Drugs mentioned

• LY3857210 (LY3857210)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 2 | Status: COMPLETED | Results posted: 2024-08-07